IN THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the present application.

1 (previously presented). A compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer, wherein the compound corresponds in structure to Formula I:



Formula I

wherein:

R_2 is selected from the group consisting of N, NH and S; wherein

if R_2 is N, then R_1 is selected from the group consisting of $-(CH_2)_3-$,$-(CH_2)_4-$, $-CH_2SCH_2$, and $-SCH_2CH_2-$;

if R_2 is S or NH, then R_1 is absent;

if R_2 is NH, then n is 1;

n has a value of zero or 1;

Z is selected from the group consisting of C_2-C_{10}-alkyl, C_2-C_{10}-alkenyl, and C_2-C_{10}-alkynyl;

R_3 is selected from the group consisting of H, C_1-C_{10}-alkyl, aryl, and aralkyl;

m has a value of zero, 1, or 2;

R_4 is selected from the group consisting of O and CH_2;

R_5 is selected from the group consisting of



wherein:

R_6 is selected from the group consisting of H, C_1-C_5-alkyl, C_1-C_5-alkoxyl, OH, F, Cl, Br, and I;

X is selected from the group consisting of O, S, NH, and NCH_3;

Y is selected from the group consisting of O and NH;

W is selected from the group consisting of S and NH.

2 (previously presented). The compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer according to claim 1, wherein:

Z is C_2-C_{10}-alkyl; and

R_5 is selected from the group consisting of



,

,



, and



;

wherein:

R_6 is selected from the group consisting of H, C_1-C_5-alkyl, C_1-C_5-alkoxyl, OH, F, Cl, Br, and I.

3 (previously presented). The compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer according to claim 1, wherein:

Z is butyl;

R_3 is H; and

R_5 is selected from the group consisting of



;

wherein:

R_6 is selected from the group consisting of H C_1-C_5-alkyl, C_1-C_5-alkoxyl, OH, F, Cl, Br, and I.

4 (previously presented). A process to prepare a compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer, wherein the compound corresponds in structure to Formula I:



Formula I

wherein:

R_2 is selected from the group consisting of N, NH and S; wherein

if R_2 is N, then R_1 is selected from the group consisting of $-(CH_2)_3-$,$-(CH_2)_4-$, $-CH_2SCH_2$, and $-SCH_2CH_2-$;

if R_2 is S or NH, then R_1 is absent;

if R_2 is NH, then n is 1;

n has a value of zero or 1;

Z is selected from the group consisting of C_2-C_{10}-alkyl, C_2-C_{10}-alkenyl, and C_2-C_{10}-alkynyl;

R_3 is selected from the group consisting of H, C_1-C_{10}-alkyl, aryl, and aralkyl;

m has a value of zero, 1, or 2;

R_4 is selected from the group consisting of O and CH_2;

R_5 is selected from the group consisting of



wherein:

R_6 is selected from the group consisting of H, C_1-C_5-alkyl, C_1-C_5-alkoxyl, OH, F, Cl, Br, and I;

X is selected from the group consisting of O, S, NH, and NCH_3;

Y is selected from the group consisting of O and NH; and

W is selected from the group consisting of S and NH

comprising:

reacting compounds according to Formula II with compounds according to Formula III according to scheme I:



II III

Scheme I

or

reacting the compounds of Formula IV with the compounds of Formula V according to scheme II:



IV V

Scheme II

wherein:

L is selected from the group consisting of Cl and Br; and

the definitions of R_1, R_2, n, Z, m, R_4 and R_5 are identical to those in Formula I.

5 (previously presented). A process according to claim 4, wherein compounds with R_3 selected from the group consisting of C_1-C_{10}-alkyl, aryl and aralkyl are obtained by alkylation of the analogues wherein R_3 is hydrogen.

6 (previously presented). A pharmaceutical composition comprising a therapeutically effective quantity of a compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer, wherein the compound corresponds in structure to Formula I



Formula I ;

wherein:

R_2 is selected from the group consisting of N, NH and S; wherein

if R_2 is N, then R_1 is selected from the group consisting of -$(CH_2)_3$-,-$(CH_2)_4$-, -CH_2SCH_2, and -SCH_2CH_2-;

if R_2 is S or NH, then R_1 is absent;

if R_2 is NH, then n is 1;

n has a value of zero or 1;

Z is selected from the group consisting of C_2-C_{10}-alkyl, C_2-C_{10}-alkenyl, and C_2-C_{10}-alkynyl;

R_3 is selected from the group consisting of H, C_1-C_{10}-alkyl, aryl, and aralkyl;

m has a value of zero, 1, or 2;

R_4 is selected from the group consisting of O and CH_2;

R_5 is selected from the group consisting of



wherein:

R_6 is selected from the group consisting of H, C_1-C_5-alkyl, C_1-C_5-alkoxyl, OH, F, Cl, Br, and I;

X is selected from the group consisting of O, S, NH, and NCH_3;

Y is selected from the group consisting of O and NH;

W is selected from the group consisting of S and NH;

and one or more pharmaceutically acceptable carriers or excipients.

7 (currently amended). The method according to claim 19 for the treatment ~~and/or prevention~~ of a pathological state wherein a 5-HT_{1A} receptor agonist is indicated.

8 (currently amended). The method according to claim 21 wherein the neuroprotection provided comprises the treatment ~~and/or prophylaxis~~ of cerebral damage produced by thromboembolic stroke or cranium-brain traumatic injuries.

9 (previously presented). The compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer according to claim 1 selected from the group consisting of

(±)2-[4-[(Chroman-2-yl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;

(±)-2-[4-[(Chroman-2-yl)methylamine]butyl]-1,3-dioxoperhydroimidazo[1,5-b]thiazol;

(±)-2-[4-[(Chroman-2-yl)methylamine]butyl]-1,3-dioxoperhydroimidazo[1,5-c]-thiazol;

(±)-3-[4-[(Chroman-2-yl)methylamine]butyl]-2,4-dioxothiazolidin;

(±)-3-[5-[(Chroman-2-yl)methylamine]pentyl]-2,4-dioxothiazolidin;

(±)-3-[6-[(Chroman-2-yl)methylamine]hexyl]-2,4-dioxothiazolidin;

2-[4-[(Naphth-1-yl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;

2-[4-[(Naphth-2-yl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;

2-[4-[2-(Naphth-1-yl)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;

3-[4-[2-(Naphth-1-yl)ethylamine]butyl]-2,4-dioxothiazolidin;

2-[4-[2-(Naphth-2-yl)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;

2-[4-[2-(Phenoxy)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;

3-[4-[2-(Phenoxy)ethylamine]butyl]-2,4-dioxothiazolidin;

2-[4-[2-(Naphth-1-oxi)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;

3-[4-[2-(Naphth-1-oxi)ethylamine]butyl]-2,4-dioxothiazolidin;

2-[4-[(Benzimidazol-2-yl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;

2-[4-[(o-Methoxyphenyl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;

2-[4-[2-(o-Methoxyphenyl)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]-imidazol;
2-[4-[3-(o-Methoxyphenyl)propylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
2-[4-[4-(o-Methoxyphenyl)butylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol; and
2-[3-[3-(o-Methoxyphenyl)propylamine]propyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol.

10 (previously presented). The compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer according to claim 1 selected from the group consisting of
2-[4-[(chroman-2-yl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;
3-[4-[(chroman-2-yl)methylamino]butyl]-2,4-dioxothiazolidine;
3-[5-[(chroman-2-yl)methylamino]pentyl]-2,4-dioxothiazolidine;
3-[6-[(chroman-2-yl)methylamino]hexyl]-2,4-dioxothiazolidine;
2-[4-[2-(phenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole; and
3-[4-[2-(phenoxy)ethylamino]butyl]-2,4-dioxothiazolidine.

11 (previously presented). The process of claim 4, wherein:

Z is C_2-C_{10}-alkyl; and

R_5 is selected from the group consisting of



,



, and ;

wherein:

R_6 is selected from the group consisting of H, C_1-C_5-alkyl, C_1-C_5-alkoxyl, OH, F, Cl, Br, and I.

12 (previously presented). The process of claim 4, wherein:

Z is butyl;

R_3 is H; and

R_5 is selected from the group consisting of



;

wherein:

R_6 is selected from the group consisting of H, C_1-C_5-alkyl, C_1-C_5-alkoxyl, OH, F, Cl, Br, and I.

13 (previously presented). The process of claim 4, wherein the compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer according to Formula I is selected from the group consisting of:
(±)2-[4-[(Chroman-2-yl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
(±)-2-[4-[(Chroman-2-yl)methylamine]butyl]-1,3-dioxoperhydroimidazo[1,5-b]thiazol;
(±)-2-[4-[(Chroman-2-yl)methylamine]butyl]-1,3-dioxoperhydroimidazo[1,5-c]-thiazol;
(±)-3-[4-[(Chroman-2-yl)methylamine]butyl]-2,4-dioxothiazolidin;
(±)-3-[5-[(Chroman-2-yl)methylamine]pentyl]-2,4-dioxothiazolidin;
(±)-3-[6-[(Chroman-2-yl)methylamine]hexyl]-2,4-dioxothiazolidin;
2-[4-[(Naphth-1-yl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
2-[4-[(Naphth-2-yl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
2-[4-[2-(Naphth-1-yl)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
3-[4-[2-(Naphth-1-yl)ethylamine]butyl]-2,4-dioxothiazolidin;
2-[4-[2-(Naphth-2-yl)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
2-[4-[2-(Phenoxy)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
3-[4-[2-(Phenoxy)ethylamine]butyl]-2,4-dioxothiazolidin;
2-[4-[2-(Naphth-1-oxi)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
3-[4-[2-(Naphth-1-oxi)ethylamine]butyl]-2,4-dioxothiazolidin;
2-[4-[(Benzimidazol-2-yl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
2-[4-[(o-Methoxyphenyl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;

2-[4-[2-(o-Methoxyphenyl)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]-imidazol;
2-[4-[3-(o-Methoxyphenyl)propylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
2-[4-[4-(o-Methoxyphenyl)butylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol; and
2-[3-[3-(o-Methoxyphenyl)propylamine]propyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol.

14 (previously presented). The process of claim 4, wherein the compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer according to Formula I is selected from the group consisting of
2-[4-[(chroman-2-yl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;
3-[4-[(chroman-2-yl)methylamino]butyl]-2,4-dioxothiazolidine;
3-[5-[(chroman-2-yl)methylamino]pentyl]-2,4-dioxothiazolidine;
3-[6-[(chroman-2-yl)methylamino]hexyl]-2,4-dioxothiazolidine;
2-[4-[2-(phenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole; and
3-[4-[2-(phenoxy)ethylamino]butyl]-2,4-dioxothiazolidine.

15 (previously presented). The pharmaceutical composition of claim 6, wherein:

Z is C_2-C_{10}-alkyl; and

R_5 is selected from the group consisting of



,



, and



;

wherein:

R_6 is selected from the group consisting of H, C_1-C_5-alkyl, C_1-C_5-alkoxyl, OH, F, Cl, Br, and I.

16 (previously presented). The pharmaceutical composition of claim 6, wherein:

Z is butyl;

R_3 is H; and

R_5 is selected from the group consisting of



;

wherein:

R_6 is selected from the group consisting of H, C_1-C_5-alkyl, C_1-C_5-alkoxyl, OH, F, Cl, Br, and I.

17 (previously presented). The pharmaceutical composition of claim 6, wherein the compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer according to Formula I is selected from the group consisting of

(±)2-[4-[(Chroman-2-yl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;

(±)-2-[4-[(Chroman-2-yl)methylamine]butyl]-1,3-dioxoperhydroimidazo[1,5-b]thiazol;

(±)-2-[4-[(Chroman-2-yl)methylamine]butyl]-1,3-dioxoperhydroimidazo[1,5-c]-thiazol;

(±)-3-[4-[(Chroman-2-yl)methylamine]butyl]-2,4-dioxothiazolidin;

(±)-3-[5-[(Chroman-2-yl)methylamine]pentyl]-2,4-dioxothiazolidin;

(±)-3-[6-[(Chroman-2-yl)methylamine]hexyl]-2,4-dioxothiazolidin;

2-[4-[(Naphth-1-yl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;

2-[4-[(Naphth-2-yl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;

2-[4-[2-(Naphth-1-yl)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;

3-[4-[2-(Naphth-1-yl)ethylamine]butyl]-2,4-dioxothiazolidin;

2-[4-[2-(Naphth-2-yl)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;

2-[4-[2-(Phenoxy)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;

3-[4-[2-(Phenoxy)ethylamine]butyl]-2,4-dioxothiazolidin;

2-[4-[2-(Naphth-1-oxi)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;

3-[4-[2-(Naphth-1-oxi)ethylamine]butyl]-2,4-dioxothiazolidin;

2-[4-[(Benzimidazol-2-yl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;

2-[4-[(o-Methoxyphenyl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
2-[4-[2-(o-Methoxyphenyl)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]-imidazol;
2-[4-[3-(o-Methoxyphenyl)propylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
2-[4-[4-(o-Methoxyphenyl)butylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol; and
2-[3-[3-(o-Methoxyphenyl)propylamine]propyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol.

18 (previously presented). The pharmaceutical composition of claim 6, wherein the compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer according to Formula I is selected from the group consisting of
2-[4-[(chroman-2-yl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;
3-[4-[(chroman-2-yl)methylamino]butyl]-2,4-dioxothiazolidine;
3-[5-[(chroman-2-yl)methylamino]pentyl]-2,4-dioxothiazolidine;
3-[6-[(chroman-2-yl)methylamino]hexyl]-2,4-dioxothiazolidine;
2-[4-[2-(phenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole; and
3-[4-[2-(phenoxy)ethylamino]butyl]-2,4-dioxothiazolidine.

19 (currently amended). A method for the treatment ~~and/or prevention~~ of a pathological state in a subject in need of such treatment ~~and/or prevention~~, wherein the method comprises administering to the subject a compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer, wherein the compound corresponds in structure to Formula I:



;

Formula I

wherein:

R_2 is selected from the group consisting of N, NH and S; wherein

if R_2 is N, then R_1 is selected from the group consisting of $-(CH_2)_3-$,$-(CH_2)_4-$, $-CH_2SCH_2$, and $-SCH_2CH_2-$;

if R_2 is S or NH, then R_1 is absent;

if R_2 is NH, then n is 1;

n has a value of zero or 1;

Z is selected from the group consisting of C_2-C_{10}-alkyl, C_2-C_{10}-alkenyl, and C_2-C_{10}-alkynyl;

R_3 is selected from the group consisting of H, C_1-C_{10}-alkyl, aryl, and aralkyl;

m has a value of zero, 1, or 2;

R_4 is selected from the group consisting of O and CH_2;

R_5 is selected from the group consisting of





, and ;

wherein:

R_6 is selected from the group consisting of H, C_1-C_5-alkyl, C_1-C_5-alkoxyl, OH, F, Cl, Br, and I;

X is selected from the group consisting of O, S, NH, and NCH_3;

Y is selected from the group consisting of O and NH;

W is selected from the group consisting of S and NH.

20 (currently amended). ~~**The method according to claim 7,**~~ **A method for the treatment of a pathological state in a subject in need of such treatment, wherein the method comprises administering to the subject a compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer, wherein the compound corresponds in structure to Formula I:**



;

Formula I

wherein:

R_2 is selected from the group consisting of N, NH and S; wherein

if R_2 is N, then R_1 is selected from the group consisting of $-(CH_2)_3-$, $-(CH_2)_4-$, $-CH_2SCH_2$, and $-SCH_2CH_2-$;

if R_2 is S or NH, then R_1 is absent;

if R_2 is NH, then n is 1;

n has a value of zero or 1;

Z is selected from the group consisting of C_2-C_{10}-alkyl, C_2-C_{10}-alkenyl, and C_2-C_{10}-alkynyl;

R_3 is selected from the group consisting of H, C_1-C_{10}-alkyl, aryl, and aralkyl;

m has a value of zero, 1, or 2;

R_4 is selected from the group consisting of O and CH_2;

R_5 is selected from the group consisting of





wherein:

R_6 is selected from the group consisting of H, C_1-C_5-alkyl, C_1-C_5-alkoxyl, OH, F, Cl, Br, and I;

X is selected from the group consisting of O, S, NH, and NCH_3;

Y is selected from the group consisting of O and NH;

W is selected from the group consisting of S and NH;

wherein **a 5-HT_{1A} agonist is indicated in the pathological state and** the pathological state is selected from the group consisting of **an** anxiety ~~**disorders**~~ **disorder**, depression and **a** mixed ~~**disorders**~~ **disorder** of anxiety and depression.

21 (previously presented). A method to provide neuroprotection to a subject in need thereof comprising administering to the subject a neuroprotective amount of a compound, a stereochemical isomer of the compound, or solvate or pharmaceutically acceptable salt of the compound or isomer, wherein the compound corresponds in structure to Formula I:



;

Formula I

wherein:

R_2 is selected from the group consisting of N, NH and S; wherein

if R_2 is N, then R_1 is selected from the group consisting of $-(CH_2)_3-$,$-(CH_2)_4-$, $-CH_2SCH_2$, and $-SCH_2CH_2-$;

if R_2 is S or NH, then R_1 is absent;

if R_2 is NH, then n is 1;

n has a value of zero or 1;

Z is selected from the group consisting of C_2-C_{10}-alkyl, C_2-C_{10}-alkenyl, and C_2-C_{10}-alkynyl;

R_3 is selected from the group consisting of H, C_1-C_{10}-alkyl, aryl, and aralkyl;

m has a value of zero, 1, or 2;

R_4 is selected from the group consisting of O and CH_2;

R_5 is selected from the group consisting of





wherein:

R_6 is selected from the group consisting of H, C_1-C_5-alkyl, C_1-C_5-alkoxyl, OH, F, Cl, Br, and I;

X is selected from the group consisting of O, S, NH, and NCH_3;

Y is selected from the group consisting of O and NH;

W is selected from the group consisting of S and NH.

22 (previously presented). The compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer according to claim 1 wherein the compound corresponds in structure to Formula Ib:



;

Formula Ib

wherein the definition of n, Z, R_3, m, R_4 and R_5 are identical to those in claim 1.

23 (previously presented). The compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer according to claim 1 wherein the compound corresponds in structure to Formula Ic:



;

Formula Ic

wherein the definition of Z, R_3, m, R_4 and R_5 are identical to those in claim 1.

24 (previously presented). The compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer according to claim 1 wherein the compound corresponds in structure to Formula Id:



;

Formula Id

wherein the definition of R_1, n, Z, R_3, m, R_4 and R_5 are identical to those in claim 1.

25 (previously presented). A compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer, wherein the compound corresponds in structure to Formula I:



;

Formula I

wherein:

R_2 is selected from the group consisting of N and S; wherein

if R_2 is N, then R_1 is selected from the group consisting of $-(CH_2)_3-$,$-(CH_2)_4-$, $-CH_2SCH_2$, and $-SCH_2CH_2-$;

if R_2 is S, then R_1 is absent;

n has a value of zero or 1;

Z is selected from the group consisting of C_2-C_{10}-alkyl, C_2-C_{10}-alkenyl, and C_2-C_{10}-alkynyl;

R_3 is selected from the group consisting of H, C_1-C_{10}-alkyl, aryl, and aralkyl;

m has a value of zero, 1, or 2;

R_4 is selected from the group consisting of O and CH_2;

R_5 is selected from the group consisting of





, and ;

wherein:

R_6 is selected from the group consisting of H, C_1-C_5-alkyl, C_1-C_5-alkoxyl, OH, F, Cl, Br, and I;

X is selected from the group consisting of O, S, NH, and NCH_3;

Y is selected from the group consisting of O and NH;

W is selected from the group consisting of S and NH.